Radius Health (RDUS) : Analyst Rating Update

Radius Health (RDUS) : Zacks Investment Research ranks Radius Health (RDUS) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 7 research analysts is 1.57, which indicates as a Buy.

Radius Health (RDUS) : 4 investment research analysts covering Radius Health (RDUS) have an average price target of $55 for the near short term. The highest target price given by the Brokerage Firm to the stock is $70 and the lowest target is $37 for the short term. Analysts expect the variance to be within $13.64 of the average price.

Radius Health (NASDAQ:RDUS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $37.97 and $37.95 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $40.20. The buying momentum continued till the end and the stock did not give up its gains. It closed at $39.64, notching a gain of 3.85% for the day. The total traded volume was 660,860 . The stock had closed at $38.17 on the previous day.

Also, HC Wainwright initiates coverage on Radius Health (NASDAQ:RDUS). The shares have now been rated Buy by the stock experts at the ratings house. HC Wainwright announces the current price target of $55 per share on Radius Health . The rating by the firm was issued on May 23, 2016. The company shares have dropped -43.76% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $84.64 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $36.01 and the 200 Day Moving Average price is recorded at $36.51.

Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Companys lead product candidate is abaloparatide (BA058), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Companys clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.